Advocacy intelligence hub — real-time data for patient organizations
Regeneron Pharmaceuticals — PHASE4
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Physician EZ Use Joint Tunnel and Trigger Kit II
Primary
Veopoz
(pozelimab-bbfg)Orphan drugRegeneron Pharmaceuticals, Inc.
Complement Inhibitor [EPC]
12.1 Mechanism of Action Pozelimab-bbfg is a human, monoclonal immunoglobulin G4 P (IgG4 P ) antibody directed against the terminal complement protein...